ArticlePloS one2018

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.

Nicholas Dompe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.